SCHEMBL2236072

SCHEMBL2236072

CCOC(=O)c1cccc(NS(=O)(=O)c2ccc(Br)cc2)c1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.75
SMN1; SMN2 Q16637 4/20 0.75
NHERF1 O14745 1/20 0.73
MAPT P10636 5/20 0.64
TCF4 P15884 2/20 0.64
CTNNB1 P35222 2/20 0.64
ITGA1 P56199 1/20 0.64
HIF1A Q16665 1/20 0.59
TP53 P04637 1/20 0.57
THRB P10828 1/20 0.57
POLB P06746 1/20 0.57
HSD17B2 P37059 1/20 0.56
GPR119 Q8TDV5 3/20 0.56
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
TSHR P16473 1/20 0.54
KMT2A Q03164 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
DDX3X O00571 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2894843 0.96 LMNA (0.71) LMNASMN1; SMN2NHERF1MAPTTCF4
SCHEMBL17331309 0.90 TCF4 (0.79) LMNASMN1; SMN2NHERF1MAPTTCF4
SCHEMBL16119561 0.89 LMNA (0.77) LMNASMN1; SMN2NHERF1MAPTTCF4
SCHEMBL1726857 0.89 LMNA (0.76) LMNASMN1; SMN2NHERF1MAPTTCF4
SCHEMBL2894616 0.89 NHERF1 (0.79) LMNASMN1; SMN2NHERF1MAPTITGA1
SCHEMBL17331344 0.88 LMNA (0.75) LMNASMN1; SMN2NHERF1MAPTTCF4
SCHEMBL13546155 0.87 TCF4 (0.80) LMNASMN1; SMN2MAPTTCF4CTNNB1
SCHEMBL13028559 0.87 LMNA (0.73) LMNASMN1; SMN2NHERF1MAPTTCF4
SCHEMBL24072230 0.85 LMNA (0.71) LMNASMN1; SMN2NHERF1MAPTTCF4
SCHEMBL30509898 0.85 LMNA (0.71) LMNASMN1; SMN2NHERF1MAPTTCF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2349990-B1 ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE PIMCO 2664 LTD (GB) 2018-05-02 EP disclosed
EP-2349990-B1 ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE PIMCO 2664 LTD (GB) 2018-05-02 EP disclosed
EP-2137141-B1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS UNIV ABERDEEN (GB) 2015-12-02 EP disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-8207167-B2 Aryl-phenyl-sulfonamide-phenylene compounds and their use PIMCO 2664 LIMITED (GB) 2012-06-26 US disclosed
US-8207167-B2 Aryl-phenyl-sulfonamide-phenylene compounds and their use PIMCO 2664 LIMITED (GB) 2012-06-26 US disclosed
US-20110190302-A1 Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use PIMCO 2664 LIMITED (GB) 2011-08-04 US disclosed
US-20110190302-A1 Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use PIMCO 2664 LIMITED (GB) 2011-08-04 US disclosed
EP-2349990-A1 ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE Pimco 2664 Limited (GB) 2011-08-03 EP disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
WO-2010032010-A1 ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE PIMCO 2664 LIMITED (GB) 2010-03-25 WO disclosed
WO-2010032010-A1 ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE PIMCO 2664 LIMITED (GB) 2010-03-25 WO disclosed
EP-2137141-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS The University Court of The University of Aberdeen (GB) 2009-12-30 EP disclosed
WO-2008114022-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-09-25 WO disclosed
WO-2008114022-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents ARSA, SOST, AHR LMNA 3163/4885SMN1; SMN2 4750/4885NHERF1 3851/4885
US-20110190302-A1 Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use SOST, PSAP, ARSA LMNA 3809/4885SMN1; SMN2 3712/4885NHERF1 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.